4-[2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid
CAS: 13182-87-1
Ref. 3D-NAA18287
1g | Descontinuado | ||
5g | Descontinuado | ||
10g | Descontinuado | ||
250mg | Descontinuado | ||
500mg | Descontinuado |
Informação sobre produto
- 4-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid
- Butanedioic acid, 1-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl] ester
- Butanedioic acid, mono(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl) ester
- Imidazole-1-ethanol, 2-methyl-5-nitro-, hydrogen succinate (ester)
- Metronidazole hemisuccinate
- Metronidazole hydrogen succinate
- Metronidazole monosuccinate
- Succinic acid, 2-(2-methyl-5-nitroimidazol-1-yl)ethyl ester
- Succinic acid, mono[2-(2-methyl-5-nitroimidazol-1-yl)ethyl] ester
- (2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl) hydrogen succinate
- Ver mais sinónimos
4-[2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid is a nitroimidazole that has been shown to be effective in the treatment of cancer. It inhibits cancer by interfering with the synthesis of DNA, leading to cell death. 4-[2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid can also inhibit bacterial growth and kill bacteria through the production of reactive oxygen species. This drug has been shown to produce genotoxic impurities in laboratory animals, which may lead to mutations and cancer. The structure of 4-[2-(2methyl 5 nitro 1 H imidazol 1 yl)ethoxy]4 oxobutanoic acid is characterized by a pyrazole ring with two methyl substituents on the nitrogen